Shopping Cart
Remove All
Your shopping cart is currently empty
Laflunimus (HR325) is a DHODH inhibitor that inhibits immunoglobulin IgM and IgG secretion in vitro and in vivo, with an IC50=2.5 μm, and exerts an immunosuppressive effect by interfering with pyrimidine metabolism, and is used in the study of neuralgia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $199 | - | In Stock | |
| 2 mg | $299 | - | In Stock |
| Description | Laflunimus (HR325) is a DHODH inhibitor that inhibits immunoglobulin IgM and IgG secretion in vitro and in vivo, with an IC50=2.5 μm, and exerts an immunosuppressive effect by interfering with pyrimidine metabolism, and is used in the study of neuralgia. |
| Targets&IC50 | IgG secretion from LPS-stimulated mouse splenocytes: 2.0 μM, IgM secretion from LPS-stimulated mouse splenocytes: 2.5 μM, IgG secretion with 50 μM uridine:60 μM, IgM secretion with 50 μM uridine: 70 μM |
| In vitro | Laflunimus (HR325) inhibited LPS-induced IgM and IgG secretion from mouse splenocytes, with IC₅₀ values of 2.5 μM and 2 μM, respectively.[1] The addition of exogenous uridine (50 μM) reversed this effect, increasing the IC₅₀ values to 70 μM for IgM and 60 μM for IgG, suggesting a pyrimidine depletion mechanism.[1] Laflunimus also suppressed LPS-induced κ light-chain surface expression in 70Z/3 cells, which was similarly reversed by uridine.[1] |
| In vivo | Laflunimus inhibited the secondary antibody response to sheep red blood cells (SRBC) in mice, with an ID₅₀ of 38 mg/kg orally.[1] Co-administration of uridine reversed immunosuppression induced by Laflunimus (50 mg/kg), whereas uridine alone had no effect and did not reverse immunosuppression caused by cyclophosphamide (10 mg/kg).[1] |
| Synonyms | HR325, HR 325 |
| Molecular Weight | 310.27 |
| Formula | C15H13F3N2O2 |
| Cas No. | 147076-36-6 |
| Smiles | N(C(/C(=C(\O)/C1CC1)/C#N)=O)C2=CC(C)=C(C(F)(F)F)C=C2 |
| Relative Density. | 1.441g/cm3 |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (128.92 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2 mg/mL (6.45 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.